277 related articles for article (PubMed ID: 21774383)
1. [Glaucoma and ocular surface].
Stefan C; Cojocaru I; Pop A
Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
[TBL] [Abstract][Full Text] [Related]
2. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
4. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
5. Ocular surface disease incidence in patients with open-angle glaucoma.
Radenković M; Stanković-Babić G; Jovanović P; Djordjević-Jocić J; Trenkić-Božinović M
Srp Arh Celok Lek; 2016; 144(7-8):376-83. PubMed ID: 29652117
[TBL] [Abstract][Full Text] [Related]
6. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
Aptel F; Denis P; Baudouin C
J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
8. Are preservatives necessary to improve efficacy of some glaucoma drops?
Irkec M; Bozkurt B; Mocan MC
Br J Ophthalmol; 2013 Dec; 97(12):1493-4. PubMed ID: 24216677
[No Abstract] [Full Text] [Related]
9. [Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs].
He XG
Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):101-4. PubMed ID: 21426837
[TBL] [Abstract][Full Text] [Related]
10. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
[TBL] [Abstract][Full Text] [Related]
11. [Morphological alterations induced by preservatives in eye drops].
Huber-van der Velden KK; Thieme H; Eichhorn M
Ophthalmologe; 2012 Nov; 109(11):1077-81. PubMed ID: 23179812
[TBL] [Abstract][Full Text] [Related]
12. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
13. [Antiglaucoma drops--with or without preservatives].
Zemba M
Oftalmologia; 2009; 53(2):26-30. PubMed ID: 19697836
[TBL] [Abstract][Full Text] [Related]
14. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
15. [Antiglaucoma drugs--content of preservatives and the patient's compliance].
Výborný P; Sejcková L
Cesk Slov Oftalmol; 2006 Jul; 62(4):270-2, 274. PubMed ID: 16895060
[TBL] [Abstract][Full Text] [Related]
16. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
17. [The deleterious effect of certain surface active agents on the ocular surface].
Ravet O
Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239
[TBL] [Abstract][Full Text] [Related]
18. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
19. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.
Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C
J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502
[TBL] [Abstract][Full Text] [Related]
20. Ocular surface disease in patients with ocular hypertension and glaucoma.
Stewart WC; Stewart JA; Nelson LA
Curr Eye Res; 2011 May; 36(5):391-8. PubMed ID: 21501071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
